Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Canaccord Drug and Device Conference 2025 (Noosa)
18 slides from Argenica Therapeutics's conference presentation, October 2025
Slide 1: Argenica Therapeutics Investor Presentation
ARGENICA THERAPEUTICS INVESTOR PRESENTATION ASX: AGN CANACCORD DRUG AND DEVICE CONFERENCE IN NOOSA OCTOBER 2025 MANAGING DIRECTOR PRESENTATION 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: Neuroprotection: The Therapeutic Opportunity
NEUROPROTECTION ARGENICA THERAPEUTICS THE THERAPEUTIC OPPORTUNITY 3 www.argenica.com.au
Slide 4: Breakthrough Neuroprotective Therapy: About ARG-007
BREAKTHROUGH NEUROPROTECTIVE THERAPY ABOUT ARG-007 MISSION Commercialise neuroprotective treatments that minimises brain damage and optimised recovery Efficacy signals in Phase 2 stroke trial following stroke & other neurological conditions ARGENICA THERAPEUTICS Clinically advanced following Phase 2
Slide 5: Our Lead Indications
OUR LEAD INDICATIONS DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 2b Efficacy Safety / Tox Safety Safety/Efficacy STROKE – ARG-007 Damage to the brain from interruption of its blood supply MOD-SEVERE TBI – ARG-007 ARGENICA THERAPEUTICS Trauma to the head or body causes a loss of consciousness HIE –
Slide 6: Key Company Metrics
KEY COMPANY METRICS $10.5M $39M +$5M CASH @ BANK 1 MARKET CAP2 NON-DILUTIVE GRANTS 3 ARGENICA THERAPEUTICS 128.1M 37% SHARES HELD BY TOP 20 + DATA SHARES ON ISSUE IN PHASE 2 STROKE TRIAL 1. Cash balance as @ 30 June 2025 6 2. Calculated with closing price on @15th October 2025 being $0.305 www.argen
Slide 7: Ischaemic Stroke Opportunity
ISCHAEMIC STROKE ARGENICA THERAPEUTICS OPPORTUNITY 7 www.argenica.com.au
Slide 8: So Why Are We Targeting Stroke First?
SO WHY ARE WE TARGETING STROKE FIRST? INCIDENCE SOCIETAL IMPLICATIONS THE IMPORTANCE OF TIME ARGENICA THERAPEUTICS 45 SECONDS ONLY 10% 1.9 MILLION How often someone will recover almost brain cells die every minute suffers an ischaemic completely, due to the extent during a stroke3 stroke in the US1
Slide 9: The Opportunity in Stroke
THE OPPORTUNITY IN STROKE Category Australia United States Number of strokes per year ~45,000 annually1 ~795,000 annually2 Cost of stroke to healthcare USD$71.55 billion in 2012 AUD$5.5 billion expected to increase to system per year in healthcare costs in 20231 USD$184.13 billion by 20303 ARGENICA
Slide 10: Phase 2 Trial Outcomes
PHASE 2 TRIAL ARGENICA THERAPEUTICS OUTCOMES 10 www.argenica.com.au
Slide 11: Successful Completion of Phase 2 Trial
SUCCESSSFUL COMPLETION OF PHASE 2 TRIAL PATIENT HAS A PATIENT IN ARRIVES AT DIAGNOSE REHAB STROKE AMBULANCE HOSPITAL STROKE TYPE THROMBECTOMY BEGINS ARGENICA THERAPEUTICS Initial screening of Administration of PATIENT OUTCOME MEASURES patients to meet inclusion 0.3mg/kg ARG-007 or Safety i.e. Advers
Slide 12: Efficacy Signals in Phase 2 Trial
EFFICACY SIGNALS IN PHASE 2 TRIAL Argenica’s Phase 2 trial for ARG-007 in AIS showed encouraging signals of efficacy 1. 2. 3. 8% 23% 15% improvement 1. 15% infarct volume (brain injury) improvement 35 improvement reduction relative to placebo in 60 50 patients with slow/poor collaterals % patietns w
Slide 13: Day to Day Functional Improvement
DAY 30 TO DAY 90 FUNCTIONAL IMPROVEMENT ARG-007 improves functional outcomes in AIS patients beyond the normal recovery, which plateaus 1. 22% 2. 11% improvement 15 differential 8 improvement differential % Patietns becoming Functionally Indepednat 6 1. 22% improvement differential: 13% 10 increase
Slide 14: Slow Collateral Patients – 30% of Participants
SLOW COLLATERAL PATIENTS – 30% OF PARTICIPANTS1 THE MOST AT-RISK PATIENTS OF VULNERABLE BRAIN TISSUE (PENUMBRA) TURNING TO INFARCT • Patients with slow/poor collaterals have highly vulnerable brain tissue that is not yet dead • This vulnerable tissue is where injury cascades are most active, ARGENIC
Slide 15: Learnings from Patient Randomisation
LEARNINGS FROM PATIENT RANDOMISATION IN BLINDED RECRUITMENT CONFIRMED ASPECT ARG-007 (n=46) Placebo (n=47) SCORE Patient ASPECTS Scores 8-10 20 (43%) 27 (57%) (confirmed by central reader) 6-7 16 (35%) 14 (30%) ARGENICA THERAPEUTICS 0-5 9 (20%) (11%) • Substantially more patients with severe brain i
Slide 16: Post Phase 2 Strategy
POST PHASE 2 STRATEGY POST HOC ANALYSIS OF PHASE 2 DATA Identify which patients benefited most, and what outcome measures are most relevant. Identify challenges in trial design that can be used to design a Phase 2b trial with higher probability of success by focusing on the right patients and ensuri
Slide 17: Encouraging Clinical Data
3# ENCOURAGING CLINICAL DATA Phase 2 acute ischaemic stroke trial results showed efficacy signals in most at risk patients with slow collaterals, and across multiple functional endpoints. Now have extensive patient data to design more targeted trial ARGENICA THERAPEUTICS 1# SOLVING LARGE UNMET NEEDS
Slide 18: Argenica Therapeutics Contact
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 18 www.argenica.com.au
Argenica Therapeutics — Canaccord Drug and Device Conference 2025 (Noosa) on 6ix